Heat player who will shock NBA world with breakout 2026-27 season appeared first on ClutchPoints. Add ClutchPoints as a Preferred Source by clicking here.
It's not quite championship-or-bust yet for the Miami Heat, but they're as close to that status as they can get. After all, the expectations for the Heat are through the roof after they brought in two-time MVP Giannis Antetokounmpo via a blockbuster trade. Antetokounmpo has had so much appreciation for the Heat's vaunted culture that landing in Miami was one of the main priorities for him this offseason — with his former team, the Milwaukee Bucks, doing him a service.
But at the end of the day, the Heat paid a heavy price to bring Antetokounmpo in. They parted ways with Tyler Herro, Jaime Jaquez Jr., Kel'el Ware, and Kasparas Jakucionis to go along with three first-round picks (2026, 2031, and 2033), a first-round pick swap (2030), and a second-round pick (2033).
The Heat did a good enough job of replacing the depth they lost, as they added veterans Tim Hardaway Jr. and Klay Thompson to serve as floor-spacers in a Giannis-centric offense. Getting Bobby Portis back in the Giannis trade was also an underrated part of that transaction. Moreover, they came to terms with Andrew Wiggins on a contract extension, securing the services of one of their most important role players through at least the 2027-28 campaign.
Watch sports LIVE with fuboTV (free trial)

#giannis

Residents near Hull City's training ground say they are concerned about safety after two players overturned their cars on the same street within weeks of each other.
Both players escaped without injury following the crashes near the club's training ground on Mill House Woods Lane in Cottingham, East Yorkshire.
Carol White, who lives on the narrow street, said: "Maybe the Football **** ociation ought to pay to do some training with them about being considerate drivers."
Hull City has not responded to requests for a comment.
Winger Sorba Thomas was involved in the first incident on 11 September, when his Land Rover overturned and ended up on its roof.

#ground #street #mill

I'm living proof of the saying that "kids keep you young." My wife and I don't need social media. We've got multiple social barometers living in our house. But my usual reaction to every new trend or slang that enters their lexicon ("cooked" and "tuff" have been the new favorites) is skepticism. Before I try to figure out how much attention I need to put into what has them hyped, I try to figure out how serious they are about their enthusiasm.
Sunday's fantasy football action left me in a similar spot. We didn't get many massive box score performances from our stars. Instead, Week 6 was about our mid- and late-round picks or waiver-wire acquisitions. And with some giving us repeat results, the storylines coming out of Sunday should have us adjusting how we approach fantasy free agency on Tuesday.
Both Trevor Lawrence and C.J. Stroud were hooping all morning. They were the perfect pivot from whatever we had to watch on TNF. But as I was watching the Texans offense, a couple of things stood out.
what a throw from Stroud, too. pic.twitter.com/fz4EbOAKvT https://t.co/2MaTqWpPgd
First, Stroud's command of the offense was at an all-time high. Jacksonville came into the game with the 12th-highest pressure rate. Houston had a twofold response. It used an extra lineman on 35.6% of its plays (a season-high), and Stroud was getting rid of the football in 2.31 seconds (a season-low). The result was not only his lowest pressure rate (8.6%) but also his highest EPA per dropback (0.35). More importantly, the Jaguars' defensive measures, which included blitzing Stroud on 31.4% of his dropbacks, didn't stop him from throwing the ball.

#fantasy

Actress Julianne Moore has shared a look inside the West Village duplex penthouse she recently renovated, where items she's thoughtfully collected for decades create a perfectly lived-in vibe.
"The Big Lebowski" star, 65, told Architectural Digest that she had her eye on the residence before it ever hit the market.
"We were so lucky to find this apartment," she said in a video tour of the home. "I think this is one of the most beautiful apartments in New York."
Located in a 1920s building that was originally a hotel, the home is on "the roof of the building" and boasts several terraces—including one with an herb garden she planted and shares with her "very close friends."
After living in a townhouse with her husband, director Brett Freundlich, and their two children for nearly 25 years, this apartment is her first time living "up high."

#building #julianne

Paramount closed its $81 billion (€72bn) purchase of Warner Bros. Discovery, the companies announced on Tuesday, forming a new Hollywood giant called Skydance.
The merger brings HBO Max, films ranging from "Harry Potter" to "Sinners", and networks including CNN under the same roof as Paramount+, CBS and ******* les such as "Top Gun" and "The Godfather".
"Today is a historic day, not just for Skydance but for our entire industry," CEO David Ellison said in a statement.
The deal further concentrates power in an industry already run by just a handful of major players. Ellison's Skydance bought Paramount in an $8bn (€7.1bn) deal last year, and set its sights on Warner soon afterwards.
What followed was a tumultuous, yearlong fight over Warner's fate. Including billions of dollars in debt, Paramount's buyout of Warner amounts to nearly $111bn (€98.6bn).

#paramount #including #deal

If Harper Beckham has no fans, it's because her elder brother, Cruz Beckham, has perished.
The budding musician had a fabulous reaction to his younger sister and budding beauty mogul, who was the topic of a conversation between British presenter Holly Willoughby and The Traitor's star, Joanne McNally.
The Irish comedian was asked by the former This Morning host which celebrity she would like to be, to which Joanne replied: "Harper Beckham," adding that she knew it "should be someone like Tina Fey."
Joanne went on to cite all the things she felt would be brilliant about being the 15-year-old, having the influence of Victoria Beckham, her upcoming beauty brand, as well as holidaying on a yacht, all being things on Joanne's list.
And the proof was in the pudding, as Cruz left a gushing comment on a clip of the moment on TikTok. "Me too, Harper is the most amazing human ever," which gained 1,239 likes.

#beckham #joanne #cruz #british

Kate Middleton showed that green is one of her go-to colors for fall. While visiting the Royal Marsden NHS Foundation Trust in London, England, on September 11, 2026, the Princess of Wales arrived in a green apple midi dress by the British brand Suzannah London. The silk dress, known as the Flippy Wiggle Dress, featured black ****** ons running down the front with a tonal belt and short, capped sleeves. The dress was a re-wear for the royal; she first stepped out in the frock on May 18, 2023, while visiting the Anna Freud Centre in London. She likes that particular dress style so much that she also stepped out in a white version of the Flippy Wiggle dress with black detailing in July 2026. The white dress was Middleton's summer choice, while the green apple version is better suited to fall.
The hospital visit was a deeply personal one for the princess; Middleton received cancer treatment at the Royal Marsden Hospital in 2024, and so her visit during fall 2026 was an opportunity to connect with current patients and hospital staff. While it was obviously a very meaningful visit, it was also fitting that she chose to wear a green dress. In fashion, green symbolizes hope and new life, so her dress was a gesture of goodwill toward those in recovery.
Read more: Pamela Anderson & Kate Middleton Love The 'No-Manicure Manicure' Right Now
Wpa Pool/Getty
Kate Middleton has become an undisputed muse of fall fashion, and her enviable wardrobe provides endlessfall outfit inspo, featuring green as her signature color for the season. She wore the green apple Suzannah London dress on September 11, 2026, as proof. A few days earlier, on September 8, 2026, the princess wore a green Emilia Wickstead dress when she and Prince William dropped off Prince George for his first day at the elite boarding school, Eton College. It seems she's all about green for these meaningful events.

#green #september #hospital

Paul Skenes honored his girlfriend Olivia "Livvy" Dunne's birthday with some adorable photos!
On Thursday, October 1, the retired gymnast turned 24, and the Pittsburgh Pirates pitcher, also 24, posted an Instagram carousel filled with photos of them to mark the occasion.
The cover shot is a snap of the couple smiling on a rooftop. Skenes wore a striped **** on-down shirt, dark pants and sneakers, while Dunne donned a matching red top-and-skirt set with flip-flops.
Instagram / paulskenes
Next, the MLB star included a candid shot of him and the influencer, both dressed up for the New York Baseball Writers' Gala in January — with Skenes sporting a bow tie and **** on-down and Dunne wearing a strapless red dress — looking at each other.

#dunne

The annual Kennedy Center Honors ceremony will move to Capital One Arena while the Kennedy Center undergoes safety ******* sments
The downtown venue holds nearly nine times more people than the Kennedy Center Opera House
President Donald Trump said renovations hinge on a court ruling about restoring his name to the institution's facade
For 50 years, artists honored by the Kennedy Center have gathered beneath the same roof to celebrate their careers. This year, that tradition will look different as the Kennedy Center Honors moves off site for the first time ever.
With the Kennedy Center's main building temporarily closed to the public while safety ******* sments continue, the center announced plans to move its annual celebration of American performing arts to Capital One Arena in downtown Washington, D.C.

#honors #move #safety #downtown

It looks like Jim Carrey is ready for his next chapter.
In Touch can confirm that the Mask star, 64, listed his three-bedroom, four-and-a-half-bathroom house in Hawaii for $35 million after it was revealed this week that he recently married girlfriend Min Ah in a small private ceremony in Los Angeles.
The actor purchased the 4,717-square-foot home, located roughly 170 feet along the water on Keawakapu Beach in Kihei, nearly a decade ago in November 2016 for $16.5 million.
Designed by Ike Kligerman Barkley, the primary residence sits under a thatched roof and is framed in Douglas fir and lined in woven bamboo, according to a listing. The great room rises into the trusses and opens fully to a covered stone lanai.
ZUMAPRESS.com / MEGA

#carrey #beach #november

Is there any investment market segment more debated than gold (XAUUSD)? I'm not sure there is. We have "gold bugs," including those who see the yellow metal as the ***** et to own when the world goes haywire.
Then, there are the "we're going back on the gold standard" types. The ones that preceded crypto bros in believing fiat currencies weren't for this world. It follows that gold would return to its former role as the reserve currency.
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market ***** ysis you won't find anywhere else.
Of course, there are also plenty of investors who don't really think about gold investing very much, and who will simply trade it when there's a good opportunity. I'm in this camp.
Financial media pundits routinely tout gold as some sort of bulletproof allocation. Inflation worries? Own gold. Currency debasement? Own gold. Want your kitchen to be decorated like the Oval Office? You'll need a lot of gold.

#Gold #free #barchart #brief

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
Revenue over the trailing twelve months was $66.6 billion, up 4.6% and in line with its own three-year pace. Profitability did not follow. Its operating margin over the same twelve months was 10.5%, versus a three-year average of 22.4%.
Most of that gap is one purchase. Merck took a $5.7 billion charge in the second quarter of 2026, about 9% of a year's sales. It bought Terns Pharmaceuticals, and with it MK-4208, a candidate for chronic myeloid leukemia. The bill hits earnings now and the medicine arrives later.
The proof matters because of the risk hanging over this stock. The KEYTRUDA family was just over half of Merck's revenue in the second quarter of 2026. The company is openly planning for the end of that exclusivity when Keytruda loses primary U.S. patent protection in 2028. Management describes the stretch as more of a hill than a cliff, with a shallow dip and a fast return to growth.
Johnson & Johnson (JNJ) returned 56% over the same twelve months and Pfizer (PFE) 23%, so a good year for pharmaceuticals explains some of this but not Merck's lead. What separated Merck was evidence. The FDA approved LIPFENDRA, the first and only oral PCSK9 inhibitor. In the CORALreef Lipids trial it lowered LDL cholesterol by up to 60% when added to a statin.

#year #johnson

Charles Schwab is holding a neutral stance on equities. The firm favors commodities over stocks and bonds, according to chief investment strategist Liz Ann Sonders.
Sonders made the comments in a recent interview, pushing back on what she called "cookie-cutter" portfolio advice. She said allocation should hinge on each investor's time horizon, risk tolerance, need for income, and overall goals.
"It actually drives me a little crazy when people give a cookie-cutter answer to that," Sonders said. "There's no one ***** et allocation that makes sense right now."
https://www.youtube.com/wa...
Schwab oversees $13.4 trillion in client ***** ets, and Sonders pointed to that scale as proof there is no single right answer for every client.

#sonders #cutter #answer #h5jfl8lawe

Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
Let's just come right out and say it: It's a good time to sell a registered investment advisor practice.
We've all read headlines about sky-high multiples and firm owners fielding multiple calls a day from potential suitors. It's an environment where successful founders can generate tremendous value from selling their firms. The process isn't simple, however, and there are pitfalls that owners can stumble into, potentially robbing them of hard-earned enterprise value.
Adam Lewis, partner at Vedder Price, talked through these dynamics this week during a standing-room only session at the Future Proof Festival in Huntington Beach, California. While he advises on M&A across multiple industries, the world of wealth management stands apart in 2026 as the "strongest by far" in terms of dealmaking activity. The entrance of private equity buyers in the RIA **** e has been particularly significant, with the heightened competition among buyers helping ramp up valuations. It's a great environment for sellers who hope to monetize their life's work to fund their retirement lifestyle and potentially create intergenerational wealth, Lewis said. But it's important to be diligent and bring the right expertise to the table during the negotiation process.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.

#lewis

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta

Ethereum runs smart contracts on a proof-of-stake network where over a third of circulating ETH is staked, earning low single-digit yields.
Over five years, Bitcoin gained 58% while Ethereum lost 30%, exposing a stark performance gap despite Ethereum's expanding platform usage.
Spot Ethereum ETFs exclude staking yield, and IRS tax uncertainty on staking rewards continues to limit institutional capital from participating.
Just released. Our ***** ysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.
Ethereum (CRYPTO:ETH) is a blockchain built to run programs, which is why people point to it when they say crypto can do more than move money. Developers deploy code to it, users call that code, and the network's native token, ETH, pays for the computing power behind every transaction.

#ethereum #Crypto #stocks #enter

He was the sole holdout on a 12-person jury who otherwise voted to acquit Lindsay Clancy of murdering her three children — frustrating the defense and causing a mistrial.
After seven days of deliberations, and with specific instructions from Judge William Sullivan to follow the letter of the law on reasonable doubt, the jury said it still had one holdout who refused to budge. A mistrial was declared on Sept. 4.
Now, the lone juror, named Michael Desronvil, has come forward to share his side of the story, saying that he "didn't have any doubts" that Clancy was criminally responsible for the killings.
In a statement shared with Yahoo on Sept. 18 by his attorney Edward Andrew Paltzik, Desronvil said: "I didn't have any doubts. As I tried to explain different possible theories during deliberation, I kept getting cut off as if I had doubts based on the evidence presented.
"Based on all the physical evidence, key witnesses, and what the prosecution presented, I thought it was enough proof that she (Clancy) knew exactly what she was doing and planned."

#clancy #evidence

Bain Capital Ventures closed its 11th flagship fund at $1.6 billion on Wednesday, betting big on a "post-AGI world" that places AI agents as the chief economic driver of productivity.
The firm has been swapping software for something venture capital has never underwritten: AI-native companies that sell the work itself rather than the technology behind it.
Software startups made up 80% of Fund IX and around 20% of Fund X, said partner Matt Harris. For Fund X, AI-native startups made up 80% of the portfolio.
"The classic software startup is just not being born anymore," Harris said. "These companies where AI is just one feature among many, I think that's thoroughly uninteresting to us and, most importantly, to the most ambitious founders."
BCV defines "post-AGI" as AI agents being as productive as humans. This model's first proof point came in the form of Reserv, an AI-native insurance claims administration startup that the firm incubated with Altai Ventures and other partners. According to Harris, the company hit $100 million in revenue in its second full year. In May, the company raised a $125 million Series C.

#agents

Paramount Skydance will meet with California Atty. Gen. Rob Bonta's representatives next month for court-ordered settlement talks that could clear a path for David Ellison's $111-billion takeover of Warner Bros. Discovery.
The two sides will convene for two days, Oct. 14 and Oct. 15, according to court documents filed this week.
The talks come as both sides look for ways to resolve the pitched battle over Hollywood's industry-reshaping deal, which would put HBO, CBS, CNN, TBS, Food Network, Comedy Central and the Paramount and Warner Bros. studios under one roof. Bonta and 11 other Democratic state attorneys general sued in July to block it, and Ellison's team has been stoking political pressure on Bonta to retreat.
Bonta canceled a session last month after prelimary details and ground rules leaked, prompting him to accuse Paramount of "playing games" by violating a confidentiality agreement and spreading misinformation.

#bros #court #sides

VICTORIA, SEYCHELLES, September 16th, 2026, Chainwire
Bitget has published its August 2026 Proof of Reserves report, marking the 45th consecutive monthly disclosure since the program began in December 2022, with a total reserve ratio of 122% for the month. Separately, Bitget's August 2026 Protection Fund valuation report recorded an average monthly value of $382 million, backed by 5,500 BTC held as a separate protection reserve.
Bitget publishes both monthly Proof of Reserves and monthly Protection Fund valuation reports — two separate disclosures providing visibility into different parts of the platform's **** et-protection framework. The August PoR reserve ratio of 122% means Bitget's reported reserves for tracked **** ets exceeded the corresponding user balances included in the snapshot. A full per-asset breakdown is available on Bitget's Proof of Reserves page.
A reserve ratio above 100% reflects the position captured in a particular reporting snapshot and should not be interpreted as a financial audit or a guarantee of future solvency.
The Protection Fund's August valuation ranged from approximately $345.3 million on Aug 1, 2026 to $441.5 million on Aug 27, 2026, with an average monthly valuation of $382 million. Its dollar value fluctuates with Bitcoin's market price because the fund is backed by 5,500 BTC. Bitget established the fund in 2022 with an initial $300 million commitment, and its valuation remained above that level throughout August.

#proof

York Water holds the longest dividend streak in US public markets at 27 consecutive years, while WTW's $1.775B operating cash flow dwarfs its $358M dividend obligation.
Amdocs and Ituran both run near-recession-proof revenue models, with DOX posting near-100% managed services renewal rates and ITRN carrying zero debt alongside $103.7M in net cash.
All five stocks fund dividends from contracted or recurring revenue streams such as regulated rates, fee income, or subscriptions, insulating payouts from economic cycles.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
Income investors heading into the fourth quarter want payouts that don't wobble with the business cycle. The five names below share one thing: dividends funded by recurring, contracted, or fee-based revenue streams that keep flowing whether or not the macro cooperates. Each has raised its payout recently, and each trades on Nasdaq. As a grounding data point, Willis Towers Watson (NASDAQ:WTW) alone generated $360 million of first-half free cash flow, roughly double the prior-year period, giving the broker ample room to keep funding both dividends and buybacks.

#revenue #NASDAQ #Dividend

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#stage #survival

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#biontech #survival

VICTORIA, SEYCHELLES, September 16th, 2026, Chainwire
Bitget has published its August 2026 Proof of Reserves report, marking the 45th consecutive monthly disclosure since the program began in December 2022, with a total reserve ratio of 122% for the month. Separately, Bitget's August 2026 Protection Fund valuation report recorded an average monthly value of $382 million, backed by 5,500 BTC held as a separate protection reserve.
Bitget publishes both monthly Proof of Reserves and monthly Protection Fund valuation reports — two separate disclosures providing visibility into different parts of the platform's ***** et-protection framework. The August PoR reserve ratio of 122% means Bitget's reported reserves for tracked ***** ets exceeded the corresponding user balances included in the snapshot. A full per-asset breakdown is available on Bitget's Proof of Reserves page.
A reserve ratio above 100% reflects the position captured in a particular reporting snapshot and should not be interpreted as a financial audit or a guarantee of future solvency.
The Protection Fund's August valuation ranged from approximately $345.3 million on Aug 1, 2026 to $441.5 million on Aug 27, 2026, with an average monthly valuation of $382 million. Its dollar value fluctuates with Bitcoin's market price because the fund is backed by 5,500 BTC. Bitget established the fund in 2022 with an initial $300 million commitment, and its valuation remained above that level throughout August.

#valuation

On September 14, Coda Octopus Group (NASDAQ:CODA) reported third-quarter fiscal 2026 results that quietly crossed a threshold the company had never reached in its public history: positive retained earnings, after years of operating at an accumulated deficit. Revenue rose 9.2% year over year to $7.7 million, and pretax income climbed 16% to $1.8 million, even as instability in the Middle East knocked down the marine technology unit that has long been the company's calling card. The reason the quarter held together anyway comes down to where the growth actually showed up.
Defense engineering revenue jumped 68.3% to $2.7 million during the quarter, and the momentum did not look like a one-time ****** p. Sustainment spares orders have already topped $2.4 million year to date, and one prime contractor customer's new multiyear repair and sustainment award has since fed additional subcontract work back to Coda Octopus. On the newer end of the business, the company's US defense engineering team is now supporting several prime contractors building rugged, deployable RF electronic warfare systems for unmanned platforms, helicopters, airborne pods, and ground vehicles.
The DAVID diving system added its own proof points. Coda Octopus has delivered 24 DAVID systems to the US Navy to date, including 16 untethered units earlier in the year, and the Navy's authorization for use ****** sment on that untethered system was completed during the year, clearing it for full operational deployment. Since the quarter closed, the Navy has placed about $1.4 million in additional orders covering tethered systems and DAVID Flex adoption, including four units bought specifically for diving school and academy training. A European navy that already bought in is also expected to firm up a procurement roadmap later this year, while the new Nano sonar is being tested by subsea robotics OEMs and research groups for next-generation autonomous platforms. All of that arrived alongside $31.7 million in cash, no debt, and a balance sheet management says can fund acquisitions.
None of that offsets what happened in marine technology, the segment that still generates the largest share of revenue. Marine tech sales fell 15.2% to $3.4 million as customer activity slowed across the Middle East and parts of Asia, and hardware revenue specifically dropped 17.8% to $2.3 million. Improved rental utilization, with rental revenue up 131.1%, cushioned the blow but did not reverse it, and management has tied the weakness directly to geopolitical conditions it cannot control.

#revenue #david

The energy landscape is evolving rapidly, and one company looking to disrupt the status quo and redefine the future of nuclear power is NuScale Power (NYSE: SMR). NuScale is the only small modular reactor (SMR) developer to receive a Standard Design Approval from the Nuclear Regulatory Commission.
On Sept. 1, NuScale achieved a major engineering breakthrough. In collaboration with MilleniTEK, it successfully fabricated specialized boron-oxide pellets, a critical component of NuScale's cutting-edge passive emergency cooling system.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
This engineering triumph is a major step toward making safe, meltdown-proof modular nuclear power a reality. It also helps NuScale move closer to commercial deployment. But does this make NuScale Power stock a buy? Let's dive into the details and what it means for the stock.
In traditional nuclear reactors, reactivity control during nonstandard events often relies on active mechanical insertion of control rods or on powered chemical injection pumps. NuScale's 77 MWe Small Modular Reactor (SMR) design relies on passive safety mechanisms.

#power

For much of the past year, the "AI trade" has been focused on infrastructure: processors, data centers, and cloud capacity. Snowflake Inc. (NYSE:SNOW)'s blowout quarter, which was reported after the market closed on September 2, provided something unique: clear evidence that AI is translating into real, incremental spending within software companies that are closer to the end customer. The reaction echoed throughout corporate software the next morning, adding to a rally that, for Salesforce, Inc. (NYSE:CRM) in particular, had already begun for its own reasons.
Snowflake Inc. (NYSE:SNOW) boosted its fiscal 2027 product revenues target to $6.07 billion from $5.84 billion, following a 37% increase in second-quarter product revenue to $1.49 billion. CEO Sridhar Ramaswamy stated that the company's AI products accounted for around half of that growth acceleration, which ****** ysts took as implying that AI demand is increasing Snowflake's core data platform, instead of just adoption of standalone AI add-ons. UBS ****** yst Karl Keirstead said the figures, together with Palantir and Databricks' rapid growth, gave compelling proof of robust enterprise AI adoption.
Snowflake's beat rippled across enterprise software, with ServiceNow, Atlassian, Adobe, Intuit, and Salesforce, Inc. (NYSE:CRM) all up 3.5% to 6% on the same day, while the sector-wide iShares Expanded Tech-Software ETF rose 3%.
That Snowflake-driven spike was piled on top of a much bigger adjustment made by Salesforce, Inc. (NYSE:CRM) on its own. The company released its second-quarter fiscal 2027 results on August 26, a week before Snowflake Inc. (NYSE:SNOW), with revenue of $11.35 billion, up 11% year-over-year, with current remaining performance obligations up 14% to $33.5 billion and adjusted EPS of $5.90, exceeding the $3.27 consensus. Along with those results, Salesforce and Anthropic announced Claudeforce, an expanded partnership that initially brings Salesforce data, workflows and business logic directly into Claude through a plugin with 37 prebuilt sales skills. The companies plan additional integrations across Claude, Salesforce and Slack. That said, Salesforce recorded $2.61 billion in net gains on strategic investments during the quarter, which added $2.53 per share to non-GAAP EPS.
Taken together, the two events suggest that enterprise AI adoption can increase the value and consumption of established software platforms when AI is connected to existing corporate data and workflows

#billion #software #data #quarter

On September 10, IBEX Limited (NASDAQ:IBEX) held its fourth-quarter and full fiscal year 2026 earnings call, and the numbers backed up a message management has been building toward for months. The company posted record full-year revenue, adjusted EBITDA, and free cash flow, all while pitching itself as a business that has flipped the AI narrative in its favor rather than becoming its next casualty. For a sector that has spent the last two years bracing for automation to gut it, that is a notable claim to back with actual client wins.
Full-year revenue hit $644.1 million, up 15.4% organically, and fourth-quarter revenue reached $164.3 million, up 11.6% from a year earlier. That marked the sixth straight quarter of double-digit growth, a streak that suggests the momentum is not a one-off. HealthTech led the charge, climbing 38.5% to $114 million for the year and blowing past the $100 million target management had set for the segment, driven largely by demand from large insurance payers. Technology grew 27.4% in the quarter, while travel and logistics added 17.8%, helped by a new AI agent partnership with Philippine Airlines.
That Philippine Airlines deal is the clearest evidence that IBEX's Sierra AI partnership, formalized in January and announced publicly in May, is more than a slide in an investor deck. During the proof of concept, the AI agent handled interactions in English, Tagalog, and Taglish, hit resolution rates above 20%, and scored a 4.7 out of 5.0 on customer satisfaction, on par with human agents. A separate deployment for BJ's Wholesale pushed resolution rates above 40% and matched that same satisfaction score, beating the marks the client's prior BPO vendor had put up with human agents alone. The company added 17 new trophy logo clients across the year, and its top five clients now make up 33% of revenue, down from 36%, a sign the business is not leaning on a shrinking handful of accounts to carry it.
Not every line moved in the right direction. Fourth quarter GAAP net income slipped to $8.7 million from $9.6 million a year earlier, and diluted EPS fell to $0.59 from $0.66. Management pointed to training costs tied to all those new client wins, a temporary hit from shifting work out of nearshore centers into offshore ones, and higher fuel prices hitting utility and transportation costs, particularly offshore. Adjusted EBITDA margin for the quarter slipped to 12.3% from 13.9%, the same set of pressures showing up in the profitability line rather than just net income.

#revenue #fourth

Prince Harry might be back in the UK, but that doesn't mean he's returned to royal duties. In fact, both Harry and his father, King Charles, have made it clear that he is not a working royal and likely won't ever be again. Proof of that is that Harry was not invited to the funeral of Norway's King Harald.
William represented the British royal family and walked behind the monarch's coffin on Wednesday, September 9. He was accompanied by Princess Anne for the procession, which extended from the Royal Palace to Oslo Cathedral. Other foreign royals present included King Felipe VI and Queen Letizia of Spain, as well as King Carl XVI Gustaf and Queen Silvia of Sweden and King Frederik X and Queen Mary of Denmark.
More from StyleCaster
'Wounded' Harry Reportedly 'Blames' Charles for Devastating Business 'Withdrawal'-He Feels 'Injured'
William Reportedly 'Disturbed' by Harry's 'Vulgar' Act-It's a 'Betrayal'

#prince #harald

Democratic state parties announced Monday that they are launching an operation for the midterm elections they're calling the "New Battlefield Project," intended to recruit 10,000 volunteers to guard polling places in case armed federal officers show up.
Activists are planning mass protests if the Trump administration tries to interfere with voting or ballot counting. And legal scholars are distributing white papers advising judges what they should do if the government tries to seize ballots.
The unprecedented efforts are in response to President Donald Trump's equally unprecedented moves to interfere in this year's midterm elections, which include attempts to impose proof-of-citizenship requirements to register to vote and directing the Postal Service to play a central role in deciding which voters should get a mail ballot.
The anxious contingency planning as voting gets underway has become a marker for how fraught democracy has become in the country that once stood as an example to the world.
"We have never prepared for an election sabotage event like we have now," said Ezra Levin of the left-leaning group Indivisible.

#interfere